Blue Owl Capital Holdings LP Makes New $1.38 Million Investment in Janux Therapeutics, Inc. $JANX

Blue Owl Capital Holdings LP bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, HoldingsChannel reports. The firm bought 100,000 shares of the company’s stock, valued at approximately $1,380,000.

Other institutional investors have also recently made changes to their positions in the company. Aberdeen Group plc lifted its position in shares of Janux Therapeutics by 21.1% during the third quarter. Aberdeen Group plc now owns 345,476 shares of the company’s stock worth $8,443,000 after acquiring an additional 60,188 shares in the last quarter. Readystate Asset Management LP lifted its position in shares of Janux Therapeutics by 38.0% during the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after acquiring an additional 264,423 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Janux Therapeutics during the fourth quarter worth $536,000. SG Americas Securities LLC lifted its position in shares of Janux Therapeutics by 175.1% during the fourth quarter. SG Americas Securities LLC now owns 79,817 shares of the company’s stock worth $1,101,000 after acquiring an additional 50,802 shares in the last quarter. Finally, Profund Advisors LLC lifted its position in shares of Janux Therapeutics by 289.5% during the fourth quarter. Profund Advisors LLC now owns 64,022 shares of the company’s stock worth $884,000 after acquiring an additional 47,584 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Insiders Place Their Bets

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the sale, the vice president owned 32,270 shares in the company, valued at $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.90% of the stock is owned by insiders.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $14.52 on Monday. Janux Therapeutics, Inc. has a 52-week low of $12.12 and a 52-week high of $35.34. The company has a market capitalization of $885.43 million, a PE ratio of -7.89 and a beta of 2.58. The business’s fifty day moving average is $14.45 and its 200 day moving average is $16.45.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. On average, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on JANX shares. Guggenheim dropped their target price on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday, May 11th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Piper Sandler lowered their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Cantor Fitzgerald lowered their price objective on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.85.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.